Translational Immunology Section, Office of Science and Technology, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, United States.
Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Front Immunol. 2019 Dec 19;10:2972. doi: 10.3389/fimmu.2019.02972. eCollection 2019.
Janus kinase (JAK) inhibitors are widely used in the treatment of multiple autoimmune and inflammatory diseases. Immunologic and transcriptomic profiling have revealed major alterations on natural killer (NK) cell homeostasis associated with JAK inhibitions, while information on other innate lymphoid cells (ILCs) is still lacking. Herein, we observed that, in mice, the homeostatic pool of liver ILC1 was less affected by JAK inhibitors compared to the pool of NK cells present in the liver, spleen and bone marrow. JAK inhibition had overlapping effects on the transcriptome of both subsets, mainly affecting genes regulating cell cycle and apoptosis. However, the differential impact of JAK inhibition was linked to the high levels of the antiapoptotic gene Bcl2 expressed by ILC1. Our findings provide mechanistic explanations for the effects of JAK inhibitors on NK cells and ILC1 which could be of major clinically relevance.
Janus 激酶 (JAK) 抑制剂被广泛用于治疗多种自身免疫性和炎症性疾病。免疫和转录组分析揭示了与 JAK 抑制相关的自然杀伤 (NK) 细胞稳态的主要改变,而关于其他固有淋巴细胞 (ILC) 的信息仍然缺乏。在此,我们观察到,在小鼠中,与存在于肝脏、脾脏和骨髓中的 NK 细胞池相比,肝 ILC1 的稳态池受 JAK 抑制剂的影响较小。JAK 抑制对这两个亚群的转录组有重叠的影响,主要影响调节细胞周期和凋亡的基因。然而,JAK 抑制的差异影响与 ILC1 表达的高水平抗凋亡基因 Bcl2 有关。我们的研究结果为 JAK 抑制剂对 NK 细胞和 ILC1 的作用提供了机制解释,这可能具有重要的临床意义。